SCHEMBL9890810

SCHEMBL9890810

COC(C(N)=O)c1ccccc1-c1cccc(F)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.44
TUBB4A P04350 3/20 0.43
TUBB P07437 3/20 0.43
TUBA3C P0DPH7 3/20 0.43
TUBA1B P68363 3/20 0.43
TUBA4A P68366 3/20 0.43
TUBB4B P68371 3/20 0.43
TUBB3 Q13509 3/20 0.43
TUBB2A Q13885 3/20 0.43
TUBB8 Q3ZCM7 3/20 0.43
TUBA3E Q6PEY2 3/20 0.43
TUBA1A Q71U36 3/20 0.43
TUBA1C Q9BQE3 3/20 0.43
TUBB6 Q9BUF5 3/20 0.43
TUBB2B Q9BVA1 3/20 0.43
TUBB1 Q9H4B7 3/20 0.43
SLC9A1 P19634 3/20 0.40
CTSA P10619 2/20 0.38
CHRM3 P20309 2/20 0.38
RPS6KB1 P23443 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9890706 0.88 KDM4E (0.48) KDM4ETUBB4ATUBBTUBA3CTUBA1B
SCHEMBL2395021 0.85 SLC6A4 (0.50) KDM4ETUBB4ATUBBTUBA3CTUBA1B
SCHEMBL2393244 0.84 BCAT2 (0.44) FGFR1FGFR3
SCHEMBL2393363 0.84 RORC (0.43) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL2393565 0.82 PTGS2 (0.43) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL2393221 0.80 SLC9A1 (0.42) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL2393361 0.80 MAOB (0.43) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL2395248 0.79 ALDH1A1 (0.42) KDM4ESLC9A1CTSA
SCHEMBL29519490 0.77 ADRA2A (0.45) KDM4ETUBB4ATUBBTUBA3CTUBA1B
SCHEMBL9890686 0.77 TUBB4A (0.44) KDM4ETUBB4ATUBBTUBA3CTUBA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 KDM4E 829/4885TUBB4A 2195/4885TUBB 2329/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 KDM4E 829/4885TUBB4A 2195/4885TUBB 2329/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.